Second-line real-world treatment patterns and outcomes in patients with advanced/metastatic non-small cell lung cancer treated with first line immuno-oncology monotherapy by Talbot, D, Fish, SM, Ong, TJ, Flick, DE

nab-Paclitaxel/carboplatin in elderly patients with advanced squamous non-small cell lung cancer: a retrospective analysis of a Phase III trial by Gridelli C, Chen T, Ko A, O'Brien ME, Ong TJ, Socinski MA, Postmus PE

Get full text

Nab-paclitaxel + durvalumab as second- or third-line treatment of advanced NSCLC: results from ABOUND.2l+ by Govindan, R, Dols, MC, Aix, S, Postmus, PE, Lewanski, C, Bennouna, J, Fischer, J, Vidal, O, Stewart, D, Ardizoni, A, Weaver, J, Wolfsteiner, M, Reck, M, Talbot, D, Morgensztern, D, Ong, TJ

ABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC) by Morgensztern, D, Ong, TJ, Dols, MC, Aix, SP, Postmus, PE, Lewanski, C, Bennouna, J, Fischer, JR, Vidal, OJ, Stewart, DJ, Fasola, G, Ardizoni, A, Weaver, J, Wolfsteiner, M, Talbot, D, Govindan, R

Quality of life in patients with advanced NSCLC treated in second- or third-line with nab-paclitaxel + durvalumab: abound.2l+ by Talbot, D, Govindan, R, Cobo, M, Ponce Aix, S, Postmus, PE, Lewanski, C, Bennouna, J, Fischer, J, Juan-Vidal, O, Stewart, D, Ardizzoni, A, Bhore, R, Wolfsteiner, M, Reck, M, Morgensztern, D, Ong, TJ

Efficacy and safety of second- or third-line nab-paclitaxel + durvalumab in patients with advanced NSCLC (ABOUND.2L+) by Morgensztern, D, Govindan, R, Cobo, M, Ponce Aix, S, Postmus, PE, Lewanski, C, Bennouna, J, Fischer, J, Juan-Vidal, O, Stewart, D, Ardizzoni, A, Bhore, R, Wolfsteiner, M, Reck, M, Talbot, D, Ong, TJ

nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy by Thomas M, Spigel DR, Jotte RM, McCleod M, Socinski MA, Page RD, Gressot L, Knoble J, Juan O, Morgensztern D, Isla D, Kim ES, West H, Ko A, Ong TJ, Trunova N, Gridelli C

Get full text